Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Delcath Systems, Inc. - Common Stock (NQ:DCTH)

11.63 +0.38 (+3.38%)
Streaming Delayed Price Updated: 11:49 AM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Delcath Systems, Inc. - Common Stock

< Previous 1 2 Next >
Delcath Systems Issues Full Year 2025 Guidance
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference
From Delcath Systems, Inc.
Via Business Wire
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Reports First Quarter 2025 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Host First Quarter 2025 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
Beta Bionics Announces Board Appointment of Gerard Michel
From Beta Bionics, Inc.
Via GlobeNewswire
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
From Delcath Systems, Inc.
Via Business Wire
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Host Third Quarter 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
From Delcath Systems, Inc.
Via Business Wire
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
From Delcath Systems, Inc.
Via Business Wire
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.